Overexpression of the HIF hydroxylase PHD3 is a favorable prognosticator for gastric cancer

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2710-2715

  Su, Changlei ^a   Huang, Kejin ^a   Sun, Lingyu ^a   Yang, Dongdong ^a   Zheng, Hongqun ^a   Gao, Changlu ^a   Tong, Jinxue ^a   Zhang, Qifan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Differentiation; Gastric cancer; PHD3; Prognosis

Indexed keywords

PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE 3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH MUCOSA; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; DIOXYGENASES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84867987657     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0171-6     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol. 2009;71:127-64.
3. Kato Y, Yashiro M, Fuyuhiro Y, Kashiwagi S, Matsuoka J, Hirakawa T, Noda S, Aomatsu N, Hasegawa T, Matsuzaki T, Sawada T, Ohira M, Hirakawa K. Effects of acute and chronic hypoxia on the radiosensitivity of gastric and esophageal cancer cells. Anticancer Res. 2011;31(10):3369-75.
4. Osinsky S, Bubnovskaya L, Ganusevich I, Kovelskaya A, Gumenyuk L, Olijnichenko G, Merentsev S. Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin Transl Oncol. 2011;13(2):133-8.
5. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38-47.
6. Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM. Overexpression of the HIF Hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 2011;6(8):e23847.
7. Zhou J, Li K, Gu Y, Feng B, Ren G, Zhang L, Wang Y, Nie Y, Fan D. Transcriptional up-regulation of RhoE by hypoxia-inducible factor (HIF)-1 promotes epithelial to mesenchymal transition of gastric cancer cells during hypoxia. Biochem Biophys Res Commun. 2011;415(2):348-54.
8. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625-34. doi: 10.1038/onc.2009. 441.
9. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107(1):43-54.
10. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim Av, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468-72. doi: 10.1126/science.1059796;1059796.
11. Spinella F, Rosanò L, Duca MD, Castro VD, Nicotra MR, Natali PG, Bagnato A. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1α in melanoma cells. PLoS One. 2010;5(6):e11241.
12. Metzen E, Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biol Chem. 2004;385(3-4):223-30.
13. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004; 279(37):38458-65 [Epub 7 Jul 2004].
14. Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 2011;. doi: 10.1007/s10549-011-1750-5.
15. Su Y, Loos M, Giese N, Hines OJ, Diebold I, Görlach A, Metzen E, Pastorekova S, Friess H, Büchler P. PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer. 2010;103(10):1571-9.
16. Xue J, Li XB, Jiao S, Wei Y, Wu GH, Fang J. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKK-independent of hydroxylase activity. Gastroenterology. 2010;138:606-15.
17. Berra E, Ginouves A, Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep. 2006;7:41-5.
18. Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E. PHDs overactivation during chronic hypoxia desensitizes HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA. 2008;105:4745-50.
19. del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri MO. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem. 2003;278:48690-5.
20. Pescador N, Cuevas Y, Naranjo S, Alcaide M, Villar D, Landázuri MO, Peso LD. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J. 2005;390(Pt 1):189-97.
21. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G, Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J Biol Chem. 2006;281:23482-91.
22. Chen SF, Zhang J, Li XB, Luo XY, Fang J, Chen HQ. The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. Mol Cell Biochem. 2011;358:257-63.
23. Fu J, Menzies K, Freeman RS, Taubman MB. EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J Biol Chem. 2007;282:12410-8.
24. Tennant DA, Gottlieb E. HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression. J Mol Med. 2010;88:839-49.
25. Liu Y, Huo Z, Yan B, Lin X, Zhou ZN, Liang X, Zhu W, Liang D, Li L, Zhao H, Sun Y, Chen YH. Prolyl hydroxylase 3 interacts with Bcl-2 to regulate doxorubicin-induced apoptosis in H9c2 cells. Biochem Biophys Res Commun. 2010;401:231-7.
26. Lee S, Nakamura E, Yang HF, Wei WY, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005;. doi: 10.1016/j.ccr.2005.06.015.
27. Sato M, Sakota M, Nakayama K. Human PRP19 interacts with prolylhydroxylase PHD3 and inhibits cell death in hypoxia. Exp Cell Res. 2010;316:2871-82.
28. Wang YX, Li ZC, Zhang HB, Jin HF, Sun L, Dong HY, Xu M, Zhao P, Zhang B, Wang J, Pan YL, Liu LL. HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer. Cancer Biol Ther. 2010;10(4):376-82.